Charles River wraps up $179M deal for Galapagos' CRO biz

Charles River Laboratories ($CRL) has closed its bid for two CROs formerly owned by drug developer Galapagos, trading $179 million up front and up to $7 million down the line for Argenta and BioFocus. The CRO expects its new acquisitions to add about 6% to its net sales this year, and the two outfits brought in $87 million in revenue in 2013. More